MRNA seems to have entered another downward channel trend.
Using the previous resistance on the last downward channel trend we can see it can act as a sort of support, the trend also made two other downward resistances as you can see on the chart.
This makes me to believe that this could go back down to $120 where it can make a double bottom which can be a great...
AquaBounty (AQB) NASDAQ:AQB
AquaBounty is a company that deals currently in aquaculture services, specializing in the farming of bioengineered Atlantic salmon that can grow to market size faster than what the conventional market offers.
The appeal in ABQ is clear. As global natural salmon production decreases due to environmental constraints put upon by...
Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards.
With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone.
I've...
This play looks tempting ngl. NASDAQ:BNGO
Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter.
Last time I entered around $5 and avg'ED up till $5.6.
Took Profit around $14 but this chart looks promising.
Genomics is still an underrated sector and there are many supporters of its hot...
I don't invest in Pharma, and this isn't Pharma! As I understand it, the company is making implants to help counter the aging process. Very future, very cool!
I think this could be a very good week for this stock!
As always, this is not investment advice!
For this analysis, I am going to be using the same downward trend channel that I made on March 25th and it went exactly as expected. This recent spike might be coming to an end though due to being overbought on the RSI and close to hitting the resistance on the trend channel.
Although if it breaks through that resistance it can become support, keep an eye on...
This is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info...
I published multiple bearish analyses on MRNA since 145$, right now it broke through the support at $120 and if it doesnt recover today then it's most likely going to go to $110-$100.
Although if that doesn't hold it can go down to $75.
ARKG looks like a double bounce at the bottom of thee channel, which is also the 0.382 retracement of the wave 4. Probably a little bit more channeling here before we get going.
If we get a reversal here, wave 5 should bring us to anywhere between 145-160 by EoY
The founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics.
180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in...
This is not a commentary on the promising fundamentals or potential of Denali Therapeutics but rather a purely technical analysis. DNLI has been consolidating in a falling wedge pattern coming off a nice run up from August of 2020. Price seems to have found a recent bottom at the all-time 50% fib as well a s the 200ema. These are critical levels to hold but so...
HGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits...
Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30.
finance.yahoo.com
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Cellect shareholders to retain 25% of the combined Company pre-funding
Quoin has secured $25 million in committed equity funding from Altium Capital, a...
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from...
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events...
Moderna is clearly in a downtrend channel and I wouldn't be surprised if it hits $120. I have long positions opened at $139 so I will sell those tomorrow and buy back lower.
Next time when you see those upside spikes is a chart, that is and extremely bullish sign. Maybe some insider buys!
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that...
